U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H15Cl2N2O2P
Molecular Weight 261.0861
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOPHOSPHAMIDE ANHYDROUS

SMILES

C1CNP(=O)(N(CCCl)CCCl)OC1

InChI

InChIKey=CMSMOCZEIVJLDB-UHFFFAOYSA-N
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)

HIDE SMILES / InChI

Molecular Formula C7H15Cl2N2O2P
Molecular Weight 261.0861
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Cyclophosphamide (the generic name for Cytoxan, Neosar, Revimmune), also known as cytophosphane, is a nitrogen mustard alkylating agent, from the oxazophorines group. It is used to treat various types of cancer and some autoimmune disorders. It is a "prodrug"; it is converted in the liver to active forms that have chemotherapeutic activity

Originator

Curator's Comment:: Cyclophosphamide was developed by Norbert Brock and ASTA (now Baxter Oncology).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1234 μg/L
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17587 μg × h/L
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.8 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Other AEs: Bilirubin total increased, Diarrhea...
Other AEs:
Bilirubin total increased (grade 3, 20%)
Diarrhea (grade 3, 20%)
Sources: Page: p.5, 16
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
DLT: Diarrhea, Lipase increased...
Dose limiting toxicities:
Diarrhea (grade 3-5, 12%)
Lipase increased (grade 4, 4%)
Transaminases increased (grade 3-5, 12%)
Nausea and vomiting (grade 3-5, 4%)
Sources: Page: p.5, 16
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (16.7%)
Neutropenia (16.7%)
Sources: Page: p.98
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 16.7%)
Thrombocytopenia (16.7%)
Neutropenia (16.7%)
Sources: Page: p.98
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
DLT: Febrile neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Febrile neutropenia (33.3%)
Thrombocytopenia (grade 4, 16.7%)
Sources: Page: p.658
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (grade 4, 16.7%)
Constipation (grade 3, 16.7%)
Sources: Page: p.519
50 mg 1 times / day multiple, oral
MTD
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 12 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Disc. AE: Myelosuppression, Immunosuppression...
AEs leading to
discontinuation/dose reduction:
Myelosuppression
Immunosuppression
Bone marrow failure
Infection
Urinary tract toxicity
Toxicity renal
Cystitis hemorrhagic
Pyelitis
Ureteritis
Hematuria
Cardiotoxicity
Myocarditis
Myopericarditis
Pericardial effusion
Arrhythmia (NOS)
Congestive heart failure
Pulmonary toxicity
Pneumonitis
Pulmonary fibrosis
Pulmonary veno-occlusive disease
Respiratory failure
Metastases
Venoocclusive liver disease
Fetal damage
Sources: Page: p.1
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Disc. AE: Myelosuppression, Immunosuppression...
AEs leading to
discontinuation/dose reduction:
Myelosuppression
Immunosuppression
Bone marrow failure
Infection
Urinary tract toxicity
Toxicity renal
Cystitis hemorrhagic
Pyelitis
Ureteritis
Hematuria
Cardiotoxicity
Myocarditis
Myopericarditis
Pericardial effusion
Arrhythmia (NOS)
Congestive heart failure
Pulmonary toxicity
Pneumonitis
Pulmonary fibrosis
Pulmonary veno-occlusive disease
Respiratory failure
Metastases
Venoocclusive liver disease
Fetal damage
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Bilirubin total increased grade 3, 20%
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Diarrhea grade 3, 20%
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Diarrhea grade 3-5, 12%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Transaminases increased grade 3-5, 12%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Nausea and vomiting grade 3-5, 4%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Lipase increased grade 4, 4%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Neutropenia 16.7%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Thrombocytopenia 16.7%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia grade 4, 33.3%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Thrombocytopenia 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia grade 4, 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Febrile neutropenia 33.3%
DLT
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
Thrombocytopenia grade 4, 16.7%
DLT
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
Constipation grade 3, 16.7%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Thrombocytopenia grade 4, 16.7%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Neutropenia grade 4, 33.3%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Arrhythmia (NOS) Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Bone marrow failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cardiotoxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Congestive heart failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cystitis hemorrhagic Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Fetal damage Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Hematuria Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Immunosuppression Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Infection Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Metastases Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myelosuppression Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myocarditis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myopericarditis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pericardial effusion Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pneumonitis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary fibrosis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary toxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary veno-occlusive disease Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pyelitis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Respiratory failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Toxicity renal Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Ureteritis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Urinary tract toxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Venoocclusive liver disease Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Arrhythmia (NOS) Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Bone marrow failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cardiotoxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Congestive heart failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cystitis hemorrhagic Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Fetal damage Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Hematuria Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Immunosuppression Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Infection Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Metastases Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myelosuppression Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myocarditis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myopericarditis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pericardial effusion Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pneumonitis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary fibrosis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary toxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary veno-occlusive disease Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pyelitis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Respiratory failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Toxicity renal Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Ureteritis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Urinary tract toxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Venoocclusive liver disease Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
weak (co-administration study)
Comment: coadministration with ketoconazole: had small effect on CYCLOPHOSPHAMIDE plasma concentration
Page: 15.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: coadministration with ketoconazole: caused a KTZ dose-dependent decrease in main parameters of DECP (Cmax, Tmax, and AUC0–∞) and provided magnitude exposure of DECP (more than a 50% AUC decrease) as a consequence of CYP3A inhibition
PubMed

PubMed

TitleDatePubMed
Remission of active chronic hepatitis after treatment with cyclophosphamide and prednisolone. Report of four cases.
1975 Feb
Phenolization of bladder in treatment of massive intractable hematuria.
1975 Jan
Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors.
1999
[Crescentic glomerulonephritis with anti neutrophil cytoplasmic antibody in children. Cases report].
1999 Aug
Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis.
1999 Dec
[Cyclophosphamide-induced bladder cancer in a patient with Wegener granuromatosis].
1999 Jan
Increase of hematopoietic responses by triple or single helical conformer of an antitumor (1-->3)-beta-D-glucan preparation, Sonifilan, in cyclophosphamide-induced leukopenic mice.
1999 Jan
Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma.
1999 Jul
Cyclophosphamide cystitis in mice: behavioural characterisation and correlation with bladder inflammation.
1999 Jun
Prevention of cyclophosphamide-induced hemorrhagic cystitis by glucose-mannose binding plant lectins.
1999 Jun
Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy.
1999 Jun 30
Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis.
1999 Mar
Effect of dexamethasone on cyclophosphamide-induced cystitis in rats: lack of relation with bradykinin B1 receptor-mediated motor responses.
1999 Mar 12
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
1999 May
Chlorambucil-induced postclosure exencephaly and axial skeletal abnormalities in rat fetuses.
1999 May-Jun
Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna.
1999 Oct
Cyclophosphamide-associated uroepithelial toxicity.
1999 Oct 5
Increased expression of growth-associated protein (GAP-43) in lower urinary tract pathways following cyclophosphamide (CYP)-induced cystitis.
1999 Oct 9
Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?
1999 Sep 17
Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
1999 Sep-Oct
Overwhelming septic cavernous sinus thrombosis in a woman after combination of high-dose steroid and intravenous cyclophosphamide therapy for lupus nephritis.
2000
Cyclophosphamide inhibits the development of diabetes in the diabetes-prone BB rat.
2000 Aug
Limits to the "benefits" from our oncologic interventions: a case report.
2000 Aug
Regulation of cyclophosphamide-induced eosinophilia in contact sensitivity: functional roles of interleukin-5-producing CD4(+) lymphocytes.
2000 Aug 1
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
2000 Dec 15
Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction.
2000 Jan
Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice.
2000 Jan 1
Ruptured Klebsiella pneumoniae liver abscess after high-dose cyclophosphamide for severe aplastic anemia.
2000 Jul
Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
2000 Jul 15
[Cyclophosphamide-induced renal pelvic tumor--a case report].
2000 Mar
QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide.
2000 Mar 4
[Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors].
2000 Nov
Report of severe neurotoxicity with cyclophosphamide.
2000 Nov-Dec
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.
2000 Oct
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
2000 Sep
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
2000 Sep
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
2001
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
2001 Aug
Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide.
2001 Aug
Azathioprine-induced destructive cholangitis.
2001 Feb
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
2001 Feb 1
Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.
2001 Feb 15
What is proper treatment for Wegener granulomatosis?
2001 Jul 23
Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma.
2001 Jun
Transitional cell carcinoma of the urinary bladder following exposure to cyclophosphamide in childhood.
2001 Jun
Alterations in neuropeptide expression in lumbosacral bladder pathways following chronic cystitis.
2001 Mar
Contribution of alveolar phagocytes to antibiotic efficacy in an experimental lung infection with Streptococcus pneumoniae.
2001 May
Protective effect of berberine on cyclophosphamide-induced haemorrhagic cystitis in rats.
2001 May
Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice.
2001 Sep
Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Cyclophosphamide can also be administered orally (1 mg per kg per day to 5 mg per kg per day) in malignant diseases.
40-50 mg per kg in divided doses over 2 to 5 days in malignant diseases and 2 mg per kg daily for 8 to 12 weeks in minimal change nephrotic sindrome
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment:: Cyclophosphamide was tested for its ability to inhibit human lymphocyte proliferation and to modulate lymphocyte response to mitogens in vitro. At higher concentrations (20 to 160 ug/ml), the drug had a suppressive effect with a maximum suppression of 99%.
from 20 to 160 ug/ml
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:54:05 UTC 2021
Edited
by admin
on Sat Jun 26 14:54:05 UTC 2021
Record UNII
6UXW23996M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYCLOPHOSPHAMIDE ANHYDROUS
Common Name English
NSC-26271
Code English
ANHYDROUS CYCLOPHOSPHAMIDE
Common Name English
(+/-)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE
Systematic Name English
2H-1,3,2-OXAZAPHOSPHORIN-2-AMINE, N,N-BIS(2-CHLOROETHYL)TETRAHYDRO-, 2-OXIDE
Systematic Name English
CYCLOPHOSPHAMIDE [HSDB]
Common Name English
CYCLOPHOSPHAMIDE [WHO-DD]
Common Name English
CYCLOPHOSPHAMIDE LYOPHILIZED
Common Name English
CYCLOPHOSPHAMIDE ANHYDROUS [MI]
Common Name English
CYCLOPHOSPHAMIDE [INN]
Common Name English
CYCLOPHOSPHAMIDE, ANHYDROUS
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C697
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
NDF-RT N0000000236
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
EPA PESTICIDE CODE 624870
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
NDF-RT N0000175558
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
WHO-ATC L01AA01
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
NCI_THESAURUS C574
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
Code System Code Type Description
HSDB
3047
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
CAS
50-18-0
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
FDA UNII
6UXW23996M
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
EVMPD
SUB121739
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
PUBCHEM
2907
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
RXCUI
221085
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
ALTERNATIVE
EVMPD
SUB06859MIG
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
INN
878
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
DRUG BANK
DB00531
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
MERCK INDEX
M4013
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY Merck Index
EPA CompTox
50-18-0
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-015-4
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
RXCUI
1545988
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
NCI_THESAURUS
C61694
Created by admin on Sat Jun 26 14:54:06 UTC 2021 , Edited by admin on Sat Jun 26 14:54:06 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
URINE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
DEGRADENT -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION